Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Articles: DFG German National Licenses  (4)
  • 1990-1994  (3)
  • 1980-1984  (1)
Source
  • Articles: DFG German National Licenses  (4)
Material
Years
Year
Keywords
  • 1
    Electronic Resource
    Electronic Resource
    Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer (1994)
    Springer
    Cancer chemotherapy and pharmacology 33 (1994), S. 472-476 
    Details
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract A total of 23 women with stage II breast cancer receiving adjuvant cyclophosphamide, methotrexate and 5-fluorouracil had detailed pharmacokinetic monitoring performed on the first and third courses of therapy. The area under the concentration time curve (AUC) of each of these three drugs varied by a factor of 3–4 among patients. No systematic change in pharmacokinetics between the first and third courses was seen for cyclophosphamide, methotrexate or 5-fluorouracil, and the mean AUC for each of the three drugs did not change. However, significant intrapatient variability in drug pharmacokinetics was observed for all three drugs such that the AUC, clearance and half-life in an individual on the third course could not be reliably predicted from data generated on the first course. On the basis of these results, cyclophosphamide, methotrexate, and 5-fluorouracil pharmacokinetic data from one treatment would not be useful information from which the doses for subsequent courses could be determined.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00686503
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    The practical benefits of pharmacokinetics in the use of antineoplastic agents (1980)
    Springer
    Cancer chemotherapy and pharmacology 4 (1980), S. 139-145 
    Details
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Clinical pharmacokinetics has clearly had an important impact on the use of antineoplastic agents, but this influence has primarily been the result of comprehensive analyses conducted at the time of initial clinical trial. Such studies have often determined the dose, schedule, and route of administration, and have provided general guidelines for dose adjustment in patients with organ dysfunction. On the other hand, routine pharmacokinetic monitoring, while a highly effective adjunct to drug therapy in clinical specialties other than cancer, has not yet had an important effect on clinical oncology, with the obvious exception of high-dose methotrexate therapy. A number of potentially important applications of routine monitoring are pointed out in this paper, and will certainly be examined in the future as a means of dealing with pharmacokinetic variability. However, major impediments in this effort are posed by complexity of antineoplastic pharmacology and the lack of suitably sensitive, specific, and rapid assays for routine clinical use. Radioimmunoassays and competitive binding methods offer considerable hope in this effort, but the widespread application of these methods has not yet been realized in clinical practice.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00254011
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer (1994)
    Springer
    Cancer chemotherapy and pharmacology 33 (1994), S. 472-476 
    Details
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract. A total of 23 women with stage II breast cancer receiving adjuvant cyclophosphamide, methotrexate and 5-fluorouracil had detailed pharmacokinetic monitoring performed on the first and third courses of therapy. The area under the concentration time curve (AUC) of each of these three drugs varied by a factor of 3–4 among patients. No systematic change in pharmacokinetics between the first and third courses was seen for cyclophosphamide, methotrexate or 5-fluorouracil, and the mean AUC for each of the three drugs did not change. However, significant intrapatient variability in drug pharmacokinetics was observed for all three drugs such that the AUC, clearance and half-life in an individual on the third course could not be reliably predicted from data generated on the first course. On the basis of these results, cyclophosphamide, methotrexate, and 5-fluorouracil pharmacokinetic data from one treatment would not be useful information from which the doses for subsequent courses could be determined.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00686503
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    RECPAM analysis of prognostic factors in patients with Stage III breast cancer (1990)
    Springer
    Breast cancer research and treatment 16 (1990), S. 231-242 
    Details
    ISSN: 1573-7217
    Keywords: prognostic factors ; recursive partioning and amalgamation algorithm ; stage III breast cancer
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract A retrospective chart review was conducted of women with stage III breast cancer seen at the Princess Margaret Hospital between January 1977 and December 1980. Three hundred and sixty-nine patients were available for analysis. These cases were evaluated to determine the prognostic factors of patients presenting with this stage of the disease using a recursive partitioning technique, RECPAM, and a Cox regression model. A non-mathematical description of RECPAM is presented and the advantages of RECPAM over Cox analysis are discussed. The results identify primary tumour size, axillary node involvement, internal mammary node involvement, and estrogen receptor status as the most important prognostic variables. RECPAM identified 3 prognostic groups and simultaneously provided rules based on the prognostic variables to assign patients to poor, intermediate, or good prognosis categories. Patients with estrogen receptor negative tumours, or those with axillary node involvement, primary tumours 〉 5 cm, and serum alkaline phosphatase 〉 60 IU/L, or those with internal mammary node involvement, no skin changes, and serum alkaline phosphatase 〉 60 IU/L, define a group with a poor prognosis. Patients with estrogen receptor positive tumours, no axillary node involvements, and primary tumours 〉 5 cm, or estrogen receptor positive tumours, axillary node involvement, primary tumours 〉 5 cm, but serum alkaline phosphatase ≤ 60 U/L, have an intermediate prognosis. The good prognosis group consists of those patients with estrogen receptor positive tumours who have either skin changes or primary tumours ≤ 5 cm. The effect of loco-regional and systemic therapy was assessed and there was no association between treatment assignment and prognostic group. On the basis of this RECPAM analysis, we have defined important prognostic variables to be used in the design of clinical trials, and three major patient subgroups which can be used in routine oncologic practice as a guide to patient management.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01806331
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...